Cited by 2213D Printing in Biomedical ResearchMicrofluidic and Capillary Electrophoresis ApplicationsCancer Cells and Metastasis

Organ-on-a-Chip for Cancer and Immune Organs Modeling

Open access
Sun, Wujin, Luo, Zhimin, Lee, Junmin, Kim, Han‐Jun, Lee, KangJu, Tebon, Peyton, Feng, Yudi, Dokmeci, Mehmet R. +2 more·2019·Advanced Healthcare Materials

Abstract

Bridging the gap between findings in preclinical 2D cell culture models and in vivo tissue cultures has been challenging; the simple microenvironment of 2D monolayer culture systems may not capture the cellular response to drugs accurately. Three‐dimensional organotypic models have gained increasing interest due to their ability to recreate precise cellular organizations. These models facilitate investigation of the interactions between different sub‐tissue level components through providing physiologically relevant microenvironments for cells in vitro. The incorporation of human‐sourced tissues into these models further enables personalized prediction of drug responses. Integration of microfluidic units into the 3D models can be used to control their local environment, dynamic simulation of cell behaviors, and real‐time readout of drug testing data. Cancer and immune system related diseases are severe burdens to our health care system and have created an urgent need for high‐throughput, and effective drug development plans. This review focuses on recent progress in the development of “cancer‐on‐a‐chip” and “immune organs‐on‐a‐chip” systems designed to study disease progression and predict drug‐induced responses. Future challenges and opportunities are also discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adhm.201801363

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tumor-on-chip models hold promise as a cost-effective and higher-throughput resource for screening anticancer drugs.

    “Tumor-on-chip models based on these organ-on-chip systems can recreate human tumor microenvironments and now hold great promise as a new resource for cost-effective and higher-throughput screening of anticancer drugs [13,14,15,16,17] and powerful enablers of precision medicine [18].”

    From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [15]

    The Cancer-on-a-chip section says these models recreate tumor microenvironments and improve preclinical assessment of drug efficacy; the Conclusions call them promising tools for drug testing. The Introduction identifies reducing drug-development costs as a goal, and the Conclusions discuss interest in high-throughput cancer–immune models, but neither establishes that tumor-on-chip models offer cost-effective, higher-throughput anticancer-drug screening. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Tumor-on-chip systems are expected to increase the effective identification of new and better cancer therapies while minimizing non-specific toxicity.

    “These tumor-on-chip systems are expected to increase the effective identification of new and better cancer therapies while minimizing non-specific toxicity [13,14,15,16,17].”

    From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [15]

    The Cancer-on-a-chip section says these systems improve preclinical assessment of drug efficacy and describes a platform that monitored both anticancer efficacy and cardiac toxicity. The Conclusions and future perspectives section calls them promising tools for drug testing, but does not say they minimize non-specific toxicity; it also cautions that most remain early-stage prototypes. The copy provides no page numbers for these passages. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Tumor-on-chip models can recreate human tumor microenvironments.

    “Tumor-on-chip models based on these organ-on-chip systems can recreate human tumor microenvironments and now hold great promise as a new resource for cost-effective and higher-throughput screening of anticancer drugs [13,14,15,16,17] and powerful enablers of precision medicine [18].”
  • Multiorgan-on-a-chip systems were developed to evaluate the efficacy and off-target toxicity of anticancer therapeutics.

    “To solve this problem, researchers developed multiorgan-on-a-chip systems to evaluate the efficacy and off-target toxicity of anticancer therapeutics.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Zhang B, Korolj A, Lai BFL, Radisic M, Nat. Rev. Mater. 2018, 3, 257; b) Aref AR, Huang RY, Yu W, Chua KN, Sun W, Tu TY, Bai J, Sim WJ, Zervantonakis IK, Thiery JP, Kamm RD, Integr. Biol. 2013, 5, 381. PMC4039387 23172153
  2. [8]Jürgen G, Thomas B, Torsten B, Jason AB, Dong-Woo C, Paul DD, Brian D, Gabor F, Qing L, Vladimir AM, Lorenzo M, Makoto N, Wenmiao S, Shoji T, Giovanni V, Tim BFW, Tao X, James JY, Jos M, Biofabrication 2016, 8, 013001.26744832
  3. [85]Quizon N, Kwak K, Shah S, Singh A, Pierce S, J. Immunol. 2018, 200, 120.14.

Cited by

Sorted by citations

Authors
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A.
Affiliations
  • California NanoSystems Institute (US)
  • Brigham and Women's Hospital (US)
Corresponding author
  • Sengupta, Shiladitya
  • Khademhosseini, Ali
Venue
Advanced Healthcare Materials
Publisher
Wiley
Published
2019-01-03
Volume
8
Issue
4
Pages
e1801363-e1801363
ISSN
  • 2192-2640 (ISSN-L)
  • 2192-2659
OpenAlex
W2907304027
Cited by
221
References
122
Citations by year
2026: 9 · 2025: 19 · 2024: 59 · 2023: 40 · 2022: 23 · 2021: 30 · 2020: 28 · 2019: 13
FWCI
1.90
Type
journal article
Language
en
Open access
Locations
  • Advanced Healthcare Materials (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (1U01CA214411‐01A1, 1R01GM126571‐01)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
organ-on-a-chip, microfluidics, drug response prediction, personalized drug testing, anticancer drug development, immune system diseases, disease progression modeling, in vitro tissue models
MeSH terms
Neoplasms, Organoids, Models, Immunological, Cell Culture Techniques, Tissue Engineering, Lab-On-A-Chip Devices, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review